title: Surgical and chemotherapeutic experience regarding a urachal carcinoma with repeated relapse: case report and literature review.
abstract: BACKGROUND
  Urachal carcinoma is a rare tumor that is usually associated with a poor prognosis, especially the pathological type, urachal mucinous adenocarcinoma. Surgery remains the primary treatment in prolonging the overall survival time of patients.
  
  
  METHODS
  We report on a 41-year-old woman with urachal mucinous adenocarcinoma who underwent three surgeries and several courses of chemotherapy over a 42-month period. The first surgery, involving en-bloc excision of the urachal mass, partial urinary bladder, urachal ligament, and umbilicus was performed in May 2007. It is well known that the correct surgical scheme plays a key role in preventing recurrence or metastasis. However, a second debulking surgery with only a single salpingo-oophorectomy may have contributed directly to the patient's subsequent left ovarian metastasis. Therefore, we strongly recommend performing a bilateral salpingo-oophorectomy once ovarian metastasis has been detected, even if the metastasis is only present on one side. Although postoperative adjuvant chemotherapy regimens, first with Taxol, carboplatin, gemcitabine, and cisplatin, and then with IFO, EPI, and mesna were consecutively administered after the first and second surgeries, they seemed less effective, since recurrence and metastasis occurred shortly after each surgical treatment. After a third debulking surgery in June 2009, docetaxel, oxaliplatin, and capecitabine were administered. This chemotherapy regimen was chosen based on an immunohistochemical test that involved the multidrug resistance gene; this test indicated that the urachal mucinous adenocarcinoma was resistant to the two chemotherapy regimens used previously. Surprisingly, the patient exhibited a marker response to the new regimen and the metastatic foci entered into a stable disease stage. However, the patient still died of diffuse metastatic disease 1.5 years later. During the whole period of treatment, we found that serum tumor markers including CA724, CA125, CA19-9, and CEA were elevated in a linear pattern, with parallel increases in line with peritoneal carcinomatosis and parallel reductions in line with response to personalized chemotherapy.
  
  
  CONCLUSIONS
  Personalized treatment can be given to those patients who experience a poor response to initial therapy. Moreover, an immunohistochemical test for the multidrug resistance gene and serum tumor markers may supply key information in the choice of reasonable chemotherapeutics.
authors.forename: Liang
authors.initials: L
authors.lastname: Zong
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D002288:Adenocarcinoma, Mucinous / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D010052:Ovariectomy; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
references.citation: J Urol. 1998 Apr;159(4):1298
references.pmid: 9507860
references.citation: Br J Urol. 1987 Oct;60(4):372
references.pmid: 3690215
references.citation: Int J Gynecol Pathol. 2003 Apr;22(2):189-93
references.pmid: 12649676
references.citation: Int J Gynecol Pathol. 2008 Jul;27(3):366-79
references.pmid: 18580314
references.citation: Int J Clin Exp Pathol. 2010 Dec 24;4(1):118-23
references.pmid: 21228934
references.citation: Int J Gynecol Cancer. 2009 Dec;19(9):1539-41
references.pmid: 19955933
references.citation: Cancer. 1955 Jul-Aug;8(4):741-58
references.pmid: 13240656
references.citation: Cancer. 1983 Oct 1;52(7):1273-80
references.pmid: 6883290
references.citation: Urology. 1983 Apr;21(4):360-6
references.pmid: 6836822
references.citation: Urology. 1985 Sep;26(3):252-5
references.pmid: 3929441
references.citation: Cancer. 1954 Jan;7(1):119-35
references.pmid: 13126906
references.citation: J Clin Pathol. 1998 Jun;51(6):483-4
references.pmid: 9771454
references.citation: Cancer. 2006 Aug 15;107(4):721-8
references.pmid: 16826584
references.citation: Radiographics. 2001 Mar-Apr;21(2):451-61
references.pmid: 11259707
references.citation: Urology. 1993 Dec;42(6):635-9
references.pmid: 8256396
references.citation: AJR Am J Roentgenol. 2003 Apr;180(4):1183-4
references.pmid: 12646487
references.citation: J Obstet Gynaecol. 2004 Apr;24(3):332-3
references.pmid: 15203656
references.citation: Am J Surg Pathol. 2007 Dec;31(12):1788-99
references.pmid: 18043033
references.citation: Am J Surg Pathol. 2009 May;33(5):659-68
references.pmid: 19252435
references.citation: Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):143-4
references.pmid: 16257483
references.citation: J Surg Oncol. 1992 Jul;50(3):201-3
references.pmid: 1619945
references.citation: J Urol. 1994 Feb;151(2):365-6
references.pmid: 8283526
references.citation: Am J Surg Pathol. 2006 Sep;30(9):1130-9
references.pmid: 16931958
references.citation: Urology. 1997 Apr;49(4):536-40
references.pmid: 9111622
references.citation: Virchows Arch. 1995;426(5):529-32
references.pmid: 7633664
references.citation: J Obstet Gynaecol Res. 2011 Dec;37(12):1833-7
references.pmid: 21794003
references.citation: J Urol. 1984 Jan;131(1):1-8
references.pmid: 6361280
references.citation: Urology. 2001 Sep;58(3):462
references.pmid: 11549502
references.citation: Int J Urol. 2006 Aug;13(8):1123-5
references.pmid: 16903943
references.citation: Int Urol Nephrol. 1998;30(5):569-73
references.pmid: 9934799
references.citation: J Urol. 2003 Apr;169(4):1295-8
references.pmid: 12629346